Latest News and Press Releases

WEST LAFAYETTE, Ind., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th, at 4:30 p.m. EST to discuss...

- Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - - ...

WEST LAFAYETTE, Ind., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...

– Poster further demonstrates the potential of Endocyte’s SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors – – Unwanted toxicities may be controlled through the...

WEST LAFAYETTE, Ind., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...

WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...

- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 – - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients – - IND...

WEST LAFAYETTE, Ind., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th, at 4:30 p.m. EDT to discuss...

- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -  - Refocusing Efforts on Chimeric Antigen...

WEST LAFAYETTE, Ind., May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...